Can We Offset Local Recurrence in Locally Advanced Non–Small Cell Lung Cancer? The Merry-Go-Round of Radiation Dose Escalation and Stubborn Outcomes First-Line Nivolumab Plus Relatlimab Versus ...
Three-fourths of patients have 70-75% improvement at 16 weeks with zasocitinib, envudeucit ...